CJC-1295 No DAC + Ipamorelin 10mg (CJC-1295 DAC)

Name: CJC-1295 No DAC + Ipamorelin 10mg (5+5)
Brand: Volta Peptides
SKU: vp-013
Price: 49.00 USD
Availability: InStock

Research Use Only

8 sold this week6 people viewing this

$49 USD

Ordering above $1,000?Wholesale pricing →

All orders dispatched within 24hrs

Application formLyophilized powder

StorageRefrigerated

Purity98%

Weight10mg

CAS NumberN/A

Research Use Only

For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.

This blend combines CJC-1295 without DAC (5mg) and Ipamorelin (5mg) in a single vial. Researched for synergistic effects on growth hormone release pathways, combining GHRH analog and GH secretagogue mechanisms for comprehensive GH-axis studies.

Related Research News

Regulatory

CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide

CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.

May 12, 2026

Clinical Trials

CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics

CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.

May 12, 2026

Science

Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release

Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.

May 12, 2026